Lack of a pharmacokinetic effect of raltegravir on midazolam: In vitro/in vivo correlation

被引:61
作者
Iwamoto, Marian [1 ]
Kassahun, Kelem [1 ]
Troyer, Matthew D. [1 ]
Hanley, William D. [1 ]
Lu, Ping
Rhoton, Alisha [1 ]
Pefty, Amelia S. [1 ]
Ghosh, Kalyan [1 ]
Mangin, Eric [1 ]
DeNoia, Emanuel R. [2 ]
Wenning, Larissa A. [1 ]
Stone, Julie A. [1 ]
Gottesdiener, Keith M. [1 ]
Wagner, John A. [1 ]
机构
[1] Merck & Co Inc, Whitehouse Stn, NJ USA
[2] Healthcare Discoveries Inc, San Antonio, TX USA
关键词
raltegravir; HIV-1 integrase inhibitor; pharmacokinetics; midazolam; drug interaction;
D O I
10.1177/0091270007310382
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Raltegravir is a novel HIV-1 integrase inhibitor with potent in vitro activity (95% inhibitory concentration = 33 nM in 50% human serum). In vitro characterization of raltegravir inhibition potential was assessed against a panel of cytochrome P450 (CYP) enzymes. An open-label, 2-period study was conducted to assess the effect of raltegrovir on the pharmacokinetics of midazolam, a sensitive CYP 3A4 probe substrate: period 1, 2.0 mg of midazolam; period 2, 400 mg of raltegrovir every 12 hours for 14 days with 2.0 mg of midazolam on day 14. There was no meaningful in vitro effect of raltegravir on inhibition of a panel of CYP enzymes and induction of CYP 3A4. In the presence of raltegravir, midazolam area under the curve extrapolated to infinity (AUC(0-infinity) and maximum plasma concentration (C-max) geometric mean ratios were similar (geometric mean ratios and 90% confidence intervals: 0.92 [0.82, 1.031 (P =.208) and 1.03 [0.87, 1.22] (P =.751), respectively). No substantial differences were observed in T-max (P = .750) or apparent half-life (P = .533) of midazolam. Plasma levels of midazolam were not substantially affected by raltegravir, which implies that ralteoravir is not a clinically important inducer or inhibitor of CYP 3A4 and that raltegravir would not be expected to affect the pharmacokinetics of other drugs metabolized by CYP 3A4 to a clinically meaningful extent.
引用
收藏
页码:209 / 214
页数:6
相关论文
共 16 条
[1]   HIV-1 integrase: Structural organization, conformational changes, and catalysis [J].
Asante-Appiah, E ;
Skalka, AM .
ADVANCES IN VIRUS RESEARCH, VOL 52, 1999, 52 :351-369
[2]  
Back David J, 2006, Top HIV Med, V14, P88
[3]  
*DEP HHS, 2006, PAN ANT GUID AD AD
[4]   HIV integrase structure and function [J].
Esposito, D ;
Craigie, R .
ADVANCES IN VIRUS RESEARCH, VOL 52, 1999, 52 :319-333
[5]   Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial [J].
Grinsztejn, Beatriz ;
Nguyen, Bach-Yen ;
Katlama, Christine ;
Gatell, Jose M. ;
Lazzarin, Adriano ;
Vittecoq, Daniel ;
Gonzalez, Charles J. ;
Chen, Joshua ;
Harvey, Charlotte M. ;
Isaacs, Robin D. .
LANCET, 2007, 369 (9569) :1261-1269
[6]  
*HIV AID UNAIDS, 2006, REP GLOB AIDS EP
[7]  
IWAMOTO M, 2007, CLIN PHARM THER
[8]   Metabolism and disposition in humans of raltegravir (MK-0518), an Anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme [J].
Kassahun, Kelem ;
McIntosh, Ian ;
Cui, Donghui ;
Hreniuk, David ;
Merschman, Shelia ;
Lasseter, Kenneth ;
Azrolan, Neal ;
Iwamoto, Marian ;
Wagner, John A. ;
Wenning, Larissa A. .
DRUG METABOLISM AND DISPOSITION, 2007, 35 (09) :1657-1663
[9]   Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor [J].
Lu, P ;
Schrag, ML ;
Slaughter, DE ;
Raab, CE ;
Shou, MG ;
Rodrigues, AD .
DRUG METABOLISM AND DISPOSITION, 2003, 31 (11) :1352-1360
[10]   Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals [J].
Markowitz, Martin ;
Morales-Ramirez, Javier O. ;
Nguyen, Bach-Yen ;
Kovacs, Colin M. ;
Steigbigel, Roy T. ;
Cooper, David A. ;
Liporace, Ralph ;
Schwartz, Robert ;
Isaacs, Robin ;
Gilde, Lucinda R. ;
Penning, Larissa ;
Zhao, Jing ;
Teppler, Hedy .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2006, 43 (05) :509-515